New immunotherapy for lung cancer shows promise of success
In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease’s progression. The study, published April 4 in the journal The Lancet Oncology, focused on non-small cell lung cancer, which is the most common form of lung cancer.
Immunologist John Wrangle, M.D., of the Hollings Cancer Center at the Medical University of South Carolina said it’s a promising therapy that can be delivered in an outpatient setting. “People don’t talk about ‘curing’ patients with metastatic lung cancer. We now get to flirt with the idea for certain patients using immunotherapy. And at the very least we have a significant proportion of patients enjoying prolonged survival even if we can’t call them ‘cured’,” he said.
Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body’s immune system to fight cancer. One class of immunotherapeutic drugs is known as “checkpoint” inhibitors, as they target checkpoints in immune system regulation to allow the body’s natural defenses, such as white blood cells, to more effectively target the cancer.
Rubinstein said checkpoint therapies work by cutting the brake cables on the white bloods cells that are inherently able to kill tumor cells. “Tumor cells often produce suppressive factors which essentially turn the brakes on tumor-killing white blood cells. What’s unique about the therapy that we’re testing is that in addition to cutting the brake cables on white blood cells, we’re providing fuel to them so that they can more effectively kill cancer cells.”
Wrangle and Rubinstein’s therapy is a combination of a checkpoint drug, nivolumab, with a new and powerful immune stimulation drug, ALT-803. “What’s unique about our trial is that it’s two completely different types of drugs that have never been combined in humans before, and the trial demonstrated that these drugs can be safely administered, and also, there’s evidence that it may help patients where checkpoint therapy is not good enough alone,” said Rubinstein.
Patients who have stopped responding to checkpoint therapy may be helped significantly by adding ALT-803. Pre-clinical studies have shown that ALT-803 activates the immune system to mobilize lymphocytes against tumor cells and could potentially serve as an important component in combination treatments. Of the 21 patients treated, nine previously either had stable disease or responded to single-agent immunotherapy before becoming resistant to this treatment. Of these nine patients, 100 percent either had stable disease or had a partial response to the treatment used in this study.
“We can reassert control, at least in terms of stable disease, in essentially everybody we’ve treated so far,” Wrangle said.
This novel combination is a huge step forward in cancer treatment. “Whereas for decades the modalities of therapy were surgery, radiation, and chemotherapy, the last decade has brought targeted therapy, and more recently, immunotherapy. It fundamentally alters the balance of power between your body and your cancer,” Wrangle said.
A lung cancer specialist, Wrangle said 75 percent of lung cancer patients unfortunately are diagnosed at an incurable stage. “If 10 years ago you were talking about defining a five-year survival rate for metastatic non-small cell lung cancer patients, someone would laugh in your face. It would be a joke. It’s just a very different time now,” he said of the progress being made in the treatment of lung cancer.
He credits Rubinstein’s work, instrumental in the development of ALT-803, in helping to make this advance. Research into ALT-803 started years ago while Rubinstein was doing his postdoctoral training at the Scripps Research Institute. It was there that he co-discovered the powerful immune system stimulator used in this trial. The stimulator, known as IL-15 complexes, is actually a combination of an immune system growth factor and its soluble receptor. IL-15 is a growth factor for certain kinds of white blood cells including natural killer cells and T cells.
Wrangle explained that natural killer cells are the chief arm of the innate immune response. “They are an important part of anti-cancer response that haven’t been really talked about for a long time.”
Wrangle said his collaboration with Rubinstein is a powerful example of what team science can accomplish.
“His ownership of the intellectual foundation of this therapy is manifest,” Wrangle said of Rubinstein’s contribution. “He is brilliant and just works furiously to help understand how we can develop this therapy.”
Successful trials for the treatment of cancer are incredibly rare, he said. “There are very few people in human history who get the privilege of developing a new therapy for any human disease, much less cancer. Mark and I are now in this weird micro-club of folks who have developed the promise of a new therapy for cancer. That’s such an amazing privilege to be able to do that,” he said.
In contrast to other immunotherapies that require admission to a hospital, this new therapeutic combination can be administered in an outpatient setting. “The plan was to do it all as an outpatient therapy because inpatient therapy is just infeasible. My patients feel like they have the flu, but they go about their day, and it’s totally manageable. That’s the kind of revolutionary part with regard to this class of agent,” Wrangle said.
Wrangle and Rubinstein are surprised and elated at the success demonstrated in their latest study. Wrangle said the landscape of oncology is “eyeball-deep in failed trials,” so he and Rubinstein are hopeful this will provide more treatment options for patients. “The number of trials that work is miniscule, so was I surprised? I was ecstatic that it was working,” he said.
Rubinstein agreed, adding that the success of the trial is a testament to the commitment, hard work and incredible insight that Wrangle has for making a difference for his patients. “He has an amazing vision for how to bridge the gap between basic and clinical research.”
Wrangle said there’s still plenty of work to do before the new combination of drugs can be used outside of a clinical trial. “We have a lot to figure out about how to use this therapy, and we need to treat a few hundred patients in order to get a better sense of how to refine the synergy of these two classes of drugs. That’s just going to take time,” he said.
Both of the researchers, who are in their early forties, said they were motivated by the need to give lung cancer patients better options. Wrangle plans to frame the study’s publication. “I think this manuscript will be the thing that we have on the wall that we look back at 20 years from now, when we’re still working together and discovering new therapies.”
The Latest on: Lung cancer
via Google News
The Latest on: Lung cancer
Will You Change How You Treat Lung Cancer?
on April 17, 2018 at 2:10 pm
Results from a group of lung cancer trials presented at the annual meeting of the American Association for Cancer Research (AACR) could have practice-changing implications. In metastatic nonsquamous cell non-small cell lung cancer (NSCLC), the addition of ... […]
A New Lung Cancer Drug Is Shaking Up Treatment: How Does It Work?
on April 17, 2018 at 2:05 pm
An MRI scan shows a malignant lung tumor (indicated by a white arrow). Credit: BSIP/UIG Via Getty Images A drug that acts on the immune system appears to help extend the lives of patients with advanced lung cancer when given alongside standard chemotherapy ... […]
Can a simple blood test rule out lung cancer?
on April 17, 2018 at 10:07 am
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia Every year, health care providers in the United States discover more than 1.6 million lung nodules in patients. Many are "incidentally detected," meaning they are found during evaluation for an ... […]
Immunotherapy transforms lung cancer, the biggest cancer killer
on April 17, 2018 at 8:16 am
Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings. Immune therapy drugs can transform lung cancer treatment, giving patients years of extra life, doctors reported Monday. They found that pre-treating ... […]
Lung Cancer Patients Live Longer With Immune Therapy
on April 17, 2018 at 5:59 am
Odds of survival can greatly improve for people with the most common type of lung cancer if they are given a new drug that activates the immune system along with chemotherapy, a major new study has shown. The findings, medical experts say, should change ... […]
Immune therapy scores big win against lung cancer in study
on April 16, 2018 at 8:47 am
CHICAGO – For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much of its success until ... […]
Drug reduces size of some lung cancer tumors, relapse rate after surgery
on April 16, 2018 at 7:52 am
The research teams discovered new infiltration of immune cells into the lung cancer after nivolumab, an anti-PD-1 drug, was administered. Credit: Johns Hopkins Kimmel Cancer Center A drug given to early stage lung cancer patients before they undergo ... […]
Are Combination Therapies the Next Wave for Treating Lung Cancer?
on April 16, 2018 at 6:58 am
The American Cancer Society reports that lung cancer is the second most common cancer in America today, constituting about 14 percent of all new cancer diagnoses. That means about 234,030 new cases of lung cancer are expected to be diagnosed in 2018, and ... […]
Treatment combo nearly doubles survival time in lung cancer patients, study finds
on April 16, 2018 at 6:35 am
(CNN)Combining an immunotherapy drug with chemotherapy nearly doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed. […]
via Bing News